Intralesional immunotherapy of malignant melanoma with mycobacterium smegmatis cell wall skeleton combined with trehalose dimycolate (P3).
The clinical efficacy of intralesional immunotherapy utilizing Mycobacterium smegmatis cell wall skeleton (CWS) and trehalose dimycolate attached to oil droplets was investigated in 15 patients with advanced malignant melanoma. Patients received 300 microgram to 1050 microgram of the CWS combined with one-half that amount of trehalose dimycolate every 1 to 2 weeks for a total of 8 treatments. Therapy was continued if regression of injected lesions only occurred. Therapy was discontinued if regression of noninjected disease also occurred. Six of the 15 patients had regression of at least one injected lesion. Four of these 6 patients also had regression of noninjected disease lasting 4+, 6, 16 and 18+ months. Response was highly related to immune status. Six (83%) of 7 patients who reacted to one of a battery of skin tests responded. All 8 patients who did not react to skin tests failed to respond to therapy. There was no correlation of response with sex, prior therapy, disease-free interval or presence of visceral disease. Mycobacterial CWS and trehalose dimycolate is an effective immunotherapeutic agent. Additional studies of purified immunoadjuvants are warranted.
D002473:Cell Wall / Q000276:immunology; D003311:Cord Factors / Q000008:administration & dosage*; D005260:Female; D006017:Glycolipids / Q000008:administration & dosage*; D006801:Humans; D007109:Immunity; D007167:Immunotherapy; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D009161:Mycobacterium / Q000276:immunology*; D012075:Remission, Spontaneous; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*
D003311:Cord Factors; D006017:Glycolipids